Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clevidipine

FDA-approved product (emulsion, intravenous), marketed as Cleviprex.

Registered studies
34
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Clevidipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

34registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clevidipine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clevidipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

    NCT07262710 · start 2025-12-01

    Registered record
    Registry ID
    NCT07262710
    Conditions
    Post-stroke Pneumonia
    Interventions
    angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-08-19
    Enrolment
    13,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-stroke Pneumonia
    Interventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia

    NCT06063772 · start 2025-01

    Registered record
    Registry ID
    NCT06063772
    Conditions
    Hypertension
    Interventions
    Clevidipine; Lactated Ringers, Intravenous
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-01
    Completion
    2025-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionClevidipine; Lactated Ringers, Intravenous
    PhasePhase 4
    Registry statusNot yet recruiting

  • Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

    NCT06402968 · start 2024-06-01

    Registered record
    Registry ID
    NCT06402968
    Conditions
    Intracerebral Hemorrhage; Stroke; Hypertension
    Interventions
    Clevidipine Injection; Alternate IV Antihypertensive Regimen
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-06-01
    Completion
    2028-07-30
    Enrolment
    1,018

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracerebral Hemorrhage; Stroke; Hypertension
    InterventionClevidipine Injection; Alternate IV Antihypertensive Regimen
    PhaseNot recorded
    Registry statusRecruiting

  • a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency

    NCT05922436 · start 2023-07-15

    Registered record
    Registry ID
    NCT05922436
    Conditions
    Hypertensive Emergency
    Interventions
    QLG2071; Cleviprex®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-07-15
    Completion
    2024-05-25
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive Emergency
    InterventionQLG2071; Cleviprex®
    PhasePhase 3
    Registry statusUnknown

  • A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

    NCT05783557 · start 2023-05-01

    Registered record
    Registry ID
    NCT05783557
    Conditions
    Hypertensive Emergency
    Interventions
    Clevidipine Butyrate Injectable Emulsion; Cleviprex®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-05-01
    Completion
    2025-06-01
    Enrolment
    398

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive Emergency
    InterventionClevidipine Butyrate Injectable Emulsion; Cleviprex®
    PhasePhase 3
    Registry statusUnknown

  • Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

    NCT05175547 · start 2021-10-30

    Registered record
    Registry ID
    NCT05175547
    Conditions
    Stroke, Acute; Blood Pressure; Mechanical Thrombectomy
    Interventions
    Clevidipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-10-30
    Completion
    2024-02-28
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke, Acute; Blood Pressure; Mechanical Thrombectomy
    InterventionClevidipine
    PhasePhase 3
    Registry statusCompleted

  • Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency

    NCT05044364 · start 2021-10-11

    Registered record
    Registry ID
    NCT05044364
    Conditions
    Hypertensive Emergency
    Interventions
    This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-10-11
    Completion
    2022-10-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive Emergency
    InterventionThis is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
    PhasePhase 3
    Registry statusUnknown

  • Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

    NCT04670809 · start 2020-07-27

    Registered record
    Registry ID
    NCT04670809
    Conditions
    Hypertensive Emergency
    Interventions
    Clevidipine Butyrate Injection; Ncardipine Hydrochloride Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-07-27
    Completion
    2021-12
    Enrolment
    262

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive Emergency
    InterventionClevidipine Butyrate Injection; Ncardipine Hydrochloride Injection
    PhasePhase 3
    Registry statusUnknown

  • Effect of Anesthetic Conditions on Stapling Thickness and Quality

    NCT04191564 · start 2020-03

    Registered record
    Registry ID
    NCT04191564
    Conditions
    Gastrectomy
    Interventions
    low perfusion state; normal perfusion state
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-03
    Completion
    2021-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrectomy
    Interventionlow perfusion state; normal perfusion state
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study

    NCT03719001 · start 2018-10-23

    Registered record
    Registry ID
    NCT03719001
    Conditions
    Vascular Diseases
    Interventions
    Phenylephrine; Dexmedetomidine; Clevidipine; tetanic stimulus; Increased venous pressure; Calcium Chloride
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-10-23
    Completion
    2022-06-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVascular Diseases
    InterventionPhenylephrine; Dexmedetomidine; Clevidipine; tetanic stimulus +2 more
    PhaseEarly phase 1
    Registry statusCompleted

  • Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

    NCT03300479 · start 2017-06-15

    Registered record
    Registry ID
    NCT03300479
    Conditions
    Nontraumatic Intracerebral Hemorrhage, Multiple Localized
    Interventions
    Clevidipine; Urapidil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-06-15
    Completion
    2021-05-14
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNontraumatic Intracerebral Hemorrhage, Multiple Localized
    InterventionClevidipine; Urapidil
    PhasePhase 4
    Registry statusWithdrawn

  • Clevidipine in Neurocritical Patients

    NCT05168059 · start 2017-01-01

    Registered record
    Registry ID
    NCT05168059
    Conditions
    High Blood Pressure
    Interventions
    Clevidipine 0.5 MG/ML Intravenous Emulsion
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-01-01
    Completion
    2019-09-01
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Blood Pressure
    InterventionClevidipine 0.5 MG/ML Intravenous Emulsion
    PhaseNot recorded
    Registry statusCompleted

  • Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

    NCT04592380 · start 2014-08

    Registered record
    Registry ID
    NCT04592380
    Conditions
    Dyspnea; Hypertension; Acute Heart Failure
    Interventions
    Stage 1: Clevidipine (double-blinded); Stage 1: Placebo (double-blinded); Stage 2: Clevidipine (open-label); Stage 2: Standard of Care (open-label)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2014-08
    Completion
    2016-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspnea; Hypertension; Acute Heart Failure
    InterventionStage 1: Clevidipine (double-blinded); Stage 1: Placebo (double-blinded); Stage 2: Clevidipine (open-label); Stage 2: Standard of Care (open-label)
    PhasePhase 3
    Registry statusWithdrawn

  • Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

    NCT01938547 · start 2014-03-17

    Registered record
    Registry ID
    NCT01938547
    Conditions
    Pediatric Perioperative Blood Pressure Management
    Interventions
    clevidipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-03-17
    Completion
    2024-02-20
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Perioperative Blood Pressure Management
    Interventionclevidipine
    PhasePhase 4
    Registry statusTerminated

  • Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

    NCT02011321 · start 2014-03

    Registered record
    Registry ID
    NCT02011321
    Conditions
    Subarachnoid Hemorrhage; Cerebral Aneurysm; Vasospasm, Intracranial
    Interventions
    clevidipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-03
    Completion
    2018-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage; Cerebral Aneurysm; Vasospasm, Intracranial
    Interventionclevidipine
    PhasePhase 2
    Registry statusWithdrawn